Stellenwert der kardiovaskulären Magnetresonanz in der kardiovaskulären Diagnostik

Verschiedene Leitlinien empfehlen mittlerweile verstärkt den Einsatz der kardiovaskulären Magnetresonanz als wichtigen Bestandteil der nichtinvasiven Bildgebung. Die Einführung von entsprechenden Implantaten und die Kombination weiterer Techniken macht die Methode auch bei schwerkranken Patienten oder Deviceträgern möglich. In der folgenden Übersichtsarbeit wird der Stellenwert der CMR an einigen Beispielen dargestellt.

Abstract

Cardiovascular magnetic resonance (CMR) has become an accepted method for noninvasive imaging in cardiology. As part of a multimodality concept, this method can contribute valuable diagnostic aspects, often even as a first-choice method in a variety of diseases. Currently the availability is still limited, but the increasing time efficiency, technical stability and the growing competence will lead to more guideline-compliant use. The increase of CMR inclusion into guidelines of various societies is mainly based on the unique selling point of CMR, which is noninvasive myocardial tissue differentiation. In addition to efficient ischemia diagnosis, the ability to differentiate active from chronic inflammatory processes as well as the identification of reversible and irreversible damage are some aspects CMR can offer. New developments are sequences which allow for a parametric assessment of myocardial tissue based on T1- and T2-relaxation times. This is especially useful if the exact pathophysiology is unclear, as it is often the case in left ventricular hypertrophy for example. Next to the noninvasive myocardial tissue characterization CMR allows for quantitative hemodynamic assessment of the heart and the related pathologies. Flows as well as gradients can be quantified based on 2D-flow-sequences. New 4D-sequences are aiming to further characterize blood flow in the heart and the great vessels beyond flow volume and gradients. As with any diagnostic method a qualified application is crucial. In recent years, the technique itself has become much more stable and consensus recommendations of the Society for Cardiovascular Magnetic Resonance are available for the main indications, both for the MRI scan procedure and for the evaluation. Appropriate qualifications and certification opportunities are offered both nationally and internationally.

Schlüsselwörter

kardiovaskuläre Magnet-Resonanz-Tomografie - kardiale Diagnostik - Late Gadolinium Enhancement - Mapping - Stress-Untersuchung

Key words

cardiovascular magnetic resonance imaging - cardiac diagnostics - late gadolinium enhancement - mapping - stress imaging

Publication History

Article published online:
25 April 2022

• Literatur

• 1 von Knobelsdorff-Brenkenhoff F, Schulz-Menger J. Role of cardiovascular magnetic resonance in the guidelines of the European Society of Cardiology. J Cardiovasc Magn Reson Off J Soc Cardiovasc Magn Reson 2016; 18: 6 DOI: 10.1186/s12968-016-0225-6.
• 2 Schulz-Menger J, Bluemke DA, Bremerich J. et al. Standardized image interpretation and post-processing in cardiovascular magnetic resonance – 2020 update. J Cardiovasc Magn Reson 2020; 22: 19 DOI: 10.1186/s12968-020-00610-6.
• 3 Kramer CM, Barkhausen J, Bucciarelli-Ducci C. et al. Standardized cardiovascular magnetic resonance imaging (CMR) protocols: 2020 update. J Cardiovasc Magn Reson Off J Soc Cardiovasc Magn Reson 2020; 22: 17 DOI: 10.1186/s12968-020-00607-1.
• 4 von Knobelsdorff-Brenkenhoff F, Bauer WR, Deneke T. et al. Empfehlungen zu kardialen MRT-Untersuchungen bei Patienten mit Herzschrittmachern und implantierbaren Kardioverter-Defibrillatoren. Kardiologe 2019; 13: 75-86 DOI: 10.1007/s12181-019-0301-x.
• 5 RKI – Gesundheit in Deutschland 2015. Im Internet (Stand: 31.01.2022): https://www.rki.de/DE/Content/Gesundheitsmonitoring/Gesundheitsberichterstattung/GesInDtld/GesInDtld_node.html;jsessionid=B84BD51EF75E68FC02CCE2EA169B7192.internet051
• 6 Knuuti J, Wijns W, Saraste A. et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020; 41: 407-477 DOI: 10.1093/eurheartj/ehz425.
• 7 Ibanez B, James S, Agewall S. et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39: 119-177 DOI: 10.1093/eurheartj/ehx393.
• 8 Collet J-P, Thiele H, Barbato E. et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2021; 42: 1289-1367 DOI: 10.1093/eurheartj/ehaa575.
• 9 Leiner T, Bogaert J, Friedrich MG. et al. SCMR Position Paper (2020) on clinical indications for cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2020; 22: 76 DOI: 10.1186/s12968-020-00682-4.
• 10 Gulati M, Levy PD, Mukherjee D. et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2021; 144: e368-e454 DOI: 10.1161/CIR.0000000000001029.
• 11 Kim RJ, Wu E, Rafael A. et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 2000; 343: 1445-1453 DOI: 10.1056/NEJM200011163432003.
• 12 van Kranenburg M, Magro M, Thiele H. et al. Prognostic value of microvascular obstruction and infarct size, as measured by CMR in STEMI patients. JACC Cardiovasc Imaging 2014; 7: 930-939 DOI: 10.1016/j.jcmg.2014.05.010.
• 13 Eitel I, Desch S, de Waha S. et al. Long-term prognostic value of myocardial salvage assessed by cardiovascular magnetic resonance in acute reperfused myocardial infarction. Heart 2011; 97: 2038-2045 DOI: 10.1136/heartjnl-2011-300098.
• 14 Ghadri JR, Wittstein IS, Prasad A. et al. International Expert Consensus Document on Takotsubo Syndrome (Part II): Diagnostic Workup, Outcome, and Management. Eur Heart J 2018; 39: 2047-2062 DOI: 10.1093/eurheartj/ehy077.
• 15 Kwong RY, Ge Y, Steel K. et al. Cardiac Magnetic Resonance Stress Perfusion Imaging for Evaluation of Patients With Chest Pain. J Am Coll Cardiol 2019; 74: 1741-1755 DOI: 10.1016/j.jacc.2019.07.074.
• 16 Antiochos P, Ge Y, Heydari B. et al Prognostic Value of Stress Cardiac Magnetic Resonance in Patients With Known Coronary Artery Disease. JACC Cardiovasc Imaging 2021; S1936-878X(21)00559-3 DOI: 10.1016/j.jcmg.2021.06.025.
• 17 Nagel E, Greenwood JP, McCann GP. et al. Magnetic Resonance Perfusion or Fractional Flow Reserve in Coronary Disease. N Engl J Med 2019; 380: 2418-2428 DOI: 10.1056/NEJMoa1716734.
• 18 Ge Y, Pandya A, Steel K. et al. Cost-Effectiveness Analysis of Stress Cardiovascular Magnetic Resonance Imaging for Stable Chest Pain Syndromes. JACC Cardiovasc Imaging 2020; 13: 1505-1517 DOI: 10.1016/j.jcmg.2020.02.029.
• 19 Vahanian A, Beyersdorf F, Praz F. et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2021; ehab395 DOI: 10.1093/eurheartj/ehab395.
• 20 Dyverfeldt P, Bissell M, Barker AJ. et al. 4D flow cardiovascular magnetic resonance consensus statement. J Cardiovasc Magn Reson Off J Soc Cardiovasc Magn Reson 2015; 17: 72 DOI: 10.1186/s12968-015-0174-5.
• 21 Motwani M, Kidambi A, Herzog BA. et al. MR imaging of cardiac tumors and masses: a review of methods and clinical applications. Radiology 2013; 268: 26-43 DOI: 10.1148/radiol.13121239.
• 22 Pazos-López P, Pozo E, Siqueira ME. et al. Value of CMR for the differential diagnosis of cardiac masses. JACC Cardiovasc Imaging 2014; 7: 896-905 DOI: 10.1016/j.jcmg.2014.05.009.
• 23 Messroghli DR, Moon JC, Ferreira VM. et al. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI). J Cardiovasc Magn Reson Off J Soc Cardiovasc Magn Reson 2017; 19: 75 DOI: 10.1186/s12968-017-0389-8.
• 24 Rudolph A, Abdel-Aty H, Bohl S. et al. Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy relation to remodeling. J Am Coll Cardiol 2009; 53: 284-291 DOI: 10.1016/j.jacc.2008.08.064.
• 25 Elliott PM, Anastasakis A. Authors/Task Force members. et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014; 35: 2733-2779 DOI: 10.1093/eurheartj/ehu284.
• 26 Ommen SR, Mital S, Burke MA. et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2020; 142: e558-e631 DOI: 10.1161/CIR.0000000000000937.
• 27 Ferreira VM, Schulz-Menger J, Holmvang G. et al. Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations. J Am Coll Cardiol 2018; 72: 3158-3176 DOI: 10.1016/j.jacc.2018.09.072.
• 28 McDonagh TA, Metra M, Adamo M. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42: 3599-3726 DOI: 10.1093/eurheartj/ehab368.
• 29 Mavrogeni S, Bratis K, Markussis V. et al. The diagnostic role of cardiac magnetic resonance imaging in detecting myocardial inflammation in systemic lupus erythematosus. Differentiation from viral myocarditis. Lupus 2013; 22: 34-43 DOI: 10.1177/0961203312462265.
• 30 Di Marco A, Anguera I, Schmitt M. et al. Late Gadolinium Enhancement and the Risk for Ventricular Arrhythmias or Sudden Death in Dilated Cardiomyopathy: Systematic Review and Meta-Analysis. JACC Heart Fail 2017; 5: 28-38 DOI: 10.1016/j.jchf.2016.09.017.
• 31 Marcus FI, McKenna WJ, Sherrill D. et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation 2010; 121: 1533-1541 DOI: 10.1161/CIRCULATIONAHA.108.840827.
• 32 Corrado D, van Tintelen PJ, McKenna WJ. et al. Arrhythmogenic right ventricular cardiomyopathy: evaluation of the current diagnostic criteria and differential diagnosis. Eur Heart J 2020; 41: 1414-1429 DOI: 10.1093/eurheartj/ehz669.
• 33 Haugaa KH, Basso C, Badano LP. et al. Comprehensive multi-modality imaging approach in arrhythmogenic cardiomyopathy-an expert consensus document of the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2017; 18: 237-253 DOI: 10.1093/ehjci/jew229.
• 34 Leiner T, Rueckert D, Suinesiaputra A. et al. Machine learning in cardiovascular magnetic resonance: basic concepts and applications. J Cardiovasc Magn Reson Off J Soc Cardiovasc Magn Reson 2019; 21: 61 DOI: 10.1186/s12968-019-0575-y.